These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
428 related articles for article (PubMed ID: 8452705)
1. [The usefulness of reactive protein C in managing patients with ulcerative colitis and Crohn's disease]. López Morante AJ; Sáez-Royuela F; Yuguero del Moral L; Martín Lorente JL; Ojeda Giménez C Rev Esp Enferm Dig; 1993 Jan; 83(1):5-9. PubMed ID: 8452705 [TBL] [Abstract][Full Text] [Related]
2. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B; Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104 [TBL] [Abstract][Full Text] [Related]
3. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Niederau C; Backmerhoff F; Schumacher B; Niederau C Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126 [TBL] [Abstract][Full Text] [Related]
4. [Value of C-reactive protein in the evaluation of activity in ulcerative colitis and Crohn's disease]. Vucelić B; Krznarić Z; Sentić M; Milicić D; Korać B; Cvorisćec D; Stavljenić A Lijec Vjesn; 1990; 112(9-10):281-4. PubMed ID: 2093781 [TBL] [Abstract][Full Text] [Related]
5. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192 [TBL] [Abstract][Full Text] [Related]
6. [Application of chosen granulocyte markers in diagnostics of Leśniowski-Crohn's disease and ulcerative colitis--preliminary research]. Fedak D; Pawlica D; Ciećko-Michalska I; Solnica B; Mach T Przegl Lek; 2010; 67(2):114-8. PubMed ID: 20557011 [TBL] [Abstract][Full Text] [Related]
7. Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis. Letizia C; Boirivant M; De Toma G; Cerci S; Subioli S; Scuro L; Ferrari P; Pallone F Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):266-9. PubMed ID: 9759593 [TBL] [Abstract][Full Text] [Related]
8. [Serum acute phase proteins for determining disease activity of ulcerative colitis and Crohn disease]. Vucelić B; Milicić D; Krznarić Z; Korać B; Sentić M; Hadzić N; Stavljenić A; Cvorisćec D Acta Med Austriaca; 1991; 18(4):100-5. PubMed ID: 1722373 [TBL] [Abstract][Full Text] [Related]
9. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Folwaczny C; Wiebecke B; Loeschke K Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024 [TBL] [Abstract][Full Text] [Related]
10. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease]. Ciećko-Michalska I; Fedak D; Mach T Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350 [TBL] [Abstract][Full Text] [Related]
11. Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. Zilberman L; Maharshak N; Arbel Y; Rogowski O; Rozenblat M; Shapira I; Berliner S; Arber N; Dotan I Digestion; 2006; 73(4):205-9. PubMed ID: 16837810 [TBL] [Abstract][Full Text] [Related]
12. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398 [TBL] [Abstract][Full Text] [Related]
13. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108 [TBL] [Abstract][Full Text] [Related]
14. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Konrad A; Lehrke M; Schachinger V; Seibold F; Stark R; Ochsenkühn T; Parhofer KG; Göke B; Broedl UC Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1070-4. PubMed ID: 17998831 [TBL] [Abstract][Full Text] [Related]
15. Paediatric inflammatory bowel disease in New Zealand. Yap J; Wesley A; Mouat S; Chin S N Z Med J; 2008 Oct; 121(1283):19-34. PubMed ID: 18841182 [TBL] [Abstract][Full Text] [Related]
16. Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis. Becker K; Berger M; Niederau C; Frieling T Hepatogastroenterology; 1999; 46(28):2309-14. PubMed ID: 10521988 [TBL] [Abstract][Full Text] [Related]
17. Platelet activating factor in stool from patients with ulcerative colitis and Crohn's disease. Hocke M; Richter L; Bosseckert H; Eitner K Hepatogastroenterology; 1999; 46(28):2333-7. PubMed ID: 10521992 [TBL] [Abstract][Full Text] [Related]
18. Relationships between clinical data and histology of the large bowel in Crohn's disease and ulcerative colitis. Schmitz-Moormann P; Himmelmann GW; Brandes JW Pathol Annu; 1985; 20 Pt 1():281-301. PubMed ID: 3991239 [TBL] [Abstract][Full Text] [Related]
19. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases. Jung YS; Park JJ; Kim SW; Hong SP; Kim TI; Kim WH; Cheon JH Dig Liver Dis; 2012 Nov; 44(11):897-903. PubMed ID: 22721842 [TBL] [Abstract][Full Text] [Related]
20. CARD15 mutations in Dutch familial and sporadic inflammatory bowel disease and an overview of European studies. van der Linde K; Boor PP; Houwing-Duistermaat JJ; Crusius BJ; Wilson PJ; Kuipers EJ; de Rooij FW Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):449-59. PubMed ID: 17489054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]